House Bill 5988 amends Michigan’s Insurance Code to require certain health insurers and health maintenance organizations that cover prescription drugs to offer a medication synchronization program for maintenance drugs used to treat chronic long-term conditions. If the patient, physician, and pharmacist agree that synchronization is in the patient’s best interest, the insurer must allow aligned refill dates for eligible drugs, apply prorated daily cost-sharing for synchronized fills, and continue to pay normal dispensing fees on a per-drug basis rather than prorating those fees.
The bill also adds detailed requirements for step therapy protocols used by insurers and utilization review organizations. It would require step therapy to be based on transparent, evidence-based clinical practice guidelines, make those criteria available to providers and on request, and create a clear process for requesting exceptions. The bill sets specific grounds for an exception, including contraindications, likely ineffectiveness, prior failed use, medical necessity, or patient stability on the current drug, and requires decisions on exception requests or appeals within 72 hours, or 24 hours in exigent circumstances. It also requires annual reporting to the insurance director on exception requests, approvals, denials, appeals, and related medical conditions.
The bill would amend section 3406t of the Michigan Insurance Code (MCL 500.3406t) and expand state law governing prescription drug coverage, utilization review, and step therapy practices for insurers and HMOs. It would impose new operational duties on carriers and utilization review organizations, including synchronization of maintenance medications, prorated cost-sharing rules, disclosure of clinical criteria, expedited exception processing, and annual reporting to the state insurance regulator. The bill would affect insured individuals, enrollees, prescribing clinicians, pharmacists, insurers, HMOs, and utilization review entities, while preserving insurers’ ability to require generic or interchangeable biological substitutions in appropriate cases.
Based on the bill text and the absence of recorded committee testimony or votes, the measure appears generally consumer- and patient-friendly, with a focus on improving access to medications and reducing administrative barriers. Its structure suggests support for patients with chronic conditions and for providers seeking faster, more transparent coverage decisions. No formal opposition or recorded vote history is provided in the materials, so the overall sentiment cannot be measured from committee debate, but the bill’s design indicates a reform-oriented approach to prescription drug management.
The main points of potential contention are the limits the bill places on insurer utilization management tools, especially step therapy. Insurers and utilization review organizations may object to the mandated timelines, disclosure requirements, and the obligation to grant exceptions in specified circumstances, as these provisions reduce discretion and may increase administrative burden and costs. By contrast, patients, physicians, and advocates for chronic disease management are likely to support the bill’s exception standards, transparency requirements, and medication synchronization provisions because they can reduce delays, improve adherence, and make coverage decisions more predictable. The bill also preserves some insurer flexibility, such as requiring AB-rated generic or interchangeable biological substitutions, which may temper but not eliminate concerns from both sides.